Loading
A phase 3 trial testing SIM0270 in HR-positive / HER2-negative breast cancer, active and no longer recruiting.
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) is a phase 3 interventional study registered as NCT06680921, led by Jiangsu Simcere Pharmaceutical with Nanjing Zaiming Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Open-label, Phase III Study of SIM0270 Combined With Everolimus Versus Treatment of Physician's Choice in Patients With CDK4/6 Inhibitors Previously Treated, ER+/HER2- Locally Advanced or Metastatic Breast Cancer. Planned enrolment is 482 participants (actual). The study started in 2024-11-14 and primary completion is expected in 2028-08-31. No results have been posted on ClinicalTrials.gov.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.